ID

31800

Beschreibung

A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00417677

Link

https://clinicaltrials.gov/show/NCT00417677

Stichworte

Versionen (1)
  1. 28.09.18 28.09.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

28. September 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Renal Cell Carcinoma NCT00417677

Englisch

Eligibility Renal Cell Carcinoma NCT00417677

1 Formulare  
Criteria
Beschreibung

Criteria

1. histologically confirmed advanced rcc.
Beschreibung

Renal Cell Carcinoma Advanced

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0007134
UMLS CUI [1,2]
C0205179
2. up to 2 prior systemic regimens for rcc.
Beschreibung

Systemic therapy Quantity Renal Cell Carcinoma

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0007134
3. subject must have at least 1 measurable lesion that can be accurately measured in at least 1 dimension with the longest diameter ³10 mm when measured by spiral computed ct (5-mm slice thickness contiguous) or ³20 mm when measured by conventional ct (10-mm slice thickness contiguous) (lesion must be ³ 2 times the size of the slice thickness per recist).
Beschreibung

Measurable lesion Quantity | Measurable lesion Dimension Quantity | Longest Diameter Spiral CT | Slice Thickness | Longest Diameter CT

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
UMLS CUI [2,1]
C1513041
UMLS CUI [2,2]
C0439534
UMLS CUI [2,3]
C1265611
UMLS CUI [3,1]
C0552406
UMLS CUI [3,2]
C0860888
UMLS CUI [4]
C3829566
UMLS CUI [5,1]
C0552406
UMLS CUI [5,2]
C0040405
more criteria apply
Beschreibung

Criteria Additional

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1524062
exclusion criteria for dose escalation phase
Beschreibung

Exclusion Criteria Dose Escalation

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C3816728
1. subjects with known active central nervous system (cns) malignancy (primary or metastatic).
Beschreibung

Malignant Central Nervous System Neoplasm Primary | Malignant Central Nervous System Neoplasm metastatic

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0348374
UMLS CUI [1,2]
C0205225
UMLS CUI [2,1]
C0348374
UMLS CUI [2,2]
C1522484
2. prior therapy with sirolimus, temsirolimus or sunitinib.
Beschreibung

Sirolimus | temsirolimus | sunitinib

Datentyp

boolean

Alias
UMLS CUI [1]
C0072980
UMLS CUI [2]
C1707080
UMLS CUI [3]
C1176020
3. subjects receiving known strong cytochrome p450 (cyp)3a4 isoenzyme inhibitors and/or inducers. subjects receiving other cyp3a4 isoenzyme inhibitors and/or inducers not classified as strong inhibitors or inducers are eligible, provided they have been on a stable regimen for at least 4 weeks before screening.
Beschreibung

CYP3A4 Inhibitor Strong | CYP3A4 Inducer Strong

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3830624
UMLS CUI [1,2]
C0442821
UMLS CUI [2,1]
C3830625
UMLS CUI [2,2]
C0442821
more criteria apply
Beschreibung

Criteria Additional

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1524062
inclusion criteria for expanded cohort phase
Beschreibung

Inclusion criteria Cohort Phase Expanded

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0599755
UMLS CUI [1,3]
C0205390
UMLS CUI [1,4]
C0205229
1. subjects with histologically confirmed advanced rcc regardless of nephrectomy status who have received no prior systemic therapies for their disease.
Beschreibung

Renal Cell Carcinoma Advanced | Independent of Nephrectomy status | Systemic therapy Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0007134
UMLS CUI [1,2]
C0205179
UMLS CUI [2,1]
C0332291
UMLS CUI [2,2]
C1404808
UMLS CUI [3,1]
C1515119
UMLS CUI [3,2]
C0332197
2. subjects with histologically confirmed advanced rcc regardless of nephrectomy status who have a least 4 weeks since prior treatment with palliative radiation therapy, and/or surgery and resolution of all toxic effects of prior therapy to nci ctcae (version 3.0) grade £1.
Beschreibung

Renal Cell Carcinoma Advanced | Independent of Nephrectomy status | Palliative Radiation Therapy | Palliative Surgery | Toxic effects Due to Prior Therapy | Resolution CTCAE Grades

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0007134
UMLS CUI [1,2]
C0205179
UMLS CUI [2,1]
C0332291
UMLS CUI [2,2]
C1404808
UMLS CUI [3]
C3898008
UMLS CUI [4]
C0282282
UMLS CUI [5,1]
C0600688
UMLS CUI [5,2]
C0678226
UMLS CUI [5,3]
C1514463
UMLS CUI [6,1]
C1514893
UMLS CUI [6,2]
C1516728
3. subjects must have at least 1 measurable lesion that can be accurately measured in at least 1 dimension with the longest diameter ³10 mm when measured by spiral ct (5-mm slice thickness contiguous) or ³20 mm when measured by conventional ct (10-mm slice thickness contiguous) (lesion must be ³2 times the size of the slice thickness per recist).
Beschreibung

Measurable lesion Quantity | Measurable lesion Dimension Quantity | Longest Diameter Spiral CT | Slice Thickness | Longest Diameter CT

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
UMLS CUI [2,1]
C1513041
UMLS CUI [2,2]
C0439534
UMLS CUI [2,3]
C1265611
UMLS CUI [3,1]
C0552406
UMLS CUI [3,2]
C0860888
UMLS CUI [4]
C3829566
UMLS CUI [5,1]
C0552406
UMLS CUI [5,2]
C0040405
more criteria apply
Beschreibung

Criteria Additional

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1524062
exclusion criteria for the expanded cohort phase
Beschreibung

Exclusion Criteria Cohort Phase Expanded

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0599755
UMLS CUI [1,3]
C0205390
UMLS CUI [1,4]
C0205229
1. subjects with a history of a cns malignancy or metastatic disease to the cns and subjects with a known, active cns malignancy (primary or metastatic).
Beschreibung

Medical History Malignant Central Nervous System Neoplasm | Medical History Neoplasm Metastasis Central Nervous System | Malignant Central Nervous System Neoplasm Primary | Malignant Central Nervous System Neoplasm metastatic

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0348374
UMLS CUI [2,1]
C0262926
UMLS CUI [2,2]
C0027627
UMLS CUI [2,3]
C3714787
UMLS CUI [3,1]
C0348374
UMLS CUI [3,2]
C0205225
UMLS CUI [4,1]
C0348374
UMLS CUI [4,2]
C1522484
2. prior anti-vascular endothelial growth factor (anti-vegf) therapies (with either monoclonal antibodies and/or tyrosine kinase inhibitors [tkis]) and/or mtor inhibitors.
Beschreibung

Vascular Endothelial Growth Factor Inhibitor | Monoclonal Antibodies | Tyrosine kinase inhibitor | mTOR Inhibitor

Datentyp

boolean

Alias
UMLS CUI [1]
C4521299
UMLS CUI [2]
C0003250
UMLS CUI [3]
C1268567
UMLS CUI [4]
C2746052
3. subjects receiving known strong cyp3a4 isoenzyme inhibitors and/or inducers. subjects taking other cyp3a4 isoenzyme inhibitors and/or inducers not classified as strong inhibitors or inducers are eligible, provided they have been on a stable regimen for at least 4 weeks before screening.
Beschreibung

CYP3A4 Inhibitor Strong | CYP3A4 Inducer Strong

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3830624
UMLS CUI [1,2]
C0442821
UMLS CUI [2,1]
C3830625
UMLS CUI [2,2]
C0442821
more criteria apply
Beschreibung

Criteria Additional

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1524062
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Renal Cell Carcinoma NCT00417677

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Renal Cell Carcinoma Advanced
Item
1. histologically confirmed advanced rcc.
boolean
C0007134 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
Systemic therapy Quantity Renal Cell Carcinoma
Item
2. up to 2 prior systemic regimens for rcc.
boolean
C1515119 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0007134 (UMLS CUI [1,3])
Measurable lesion Quantity | Measurable lesion Dimension Quantity | Longest Diameter Spiral CT | Slice Thickness | Longest Diameter CT
Item
3. subject must have at least 1 measurable lesion that can be accurately measured in at least 1 dimension with the longest diameter ³10 mm when measured by spiral computed ct (5-mm slice thickness contiguous) or ³20 mm when measured by conventional ct (10-mm slice thickness contiguous) (lesion must be ³ 2 times the size of the slice thickness per recist).
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2,1])
C0439534 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0552406 (UMLS CUI [3,1])
C0860888 (UMLS CUI [3,2])
C3829566 (UMLS CUI [4])
C0552406 (UMLS CUI [5,1])
C0040405 (UMLS CUI [5,2])
Criteria Additional
Item
more criteria apply
boolean
C0243161 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
Exclusion Criteria Dose Escalation
Item
exclusion criteria for dose escalation phase
boolean
C0680251 (UMLS CUI [1,1])
C3816728 (UMLS CUI [1,2])
Malignant Central Nervous System Neoplasm Primary | Malignant Central Nervous System Neoplasm metastatic
Item
1. subjects with known active central nervous system (cns) malignancy (primary or metastatic).
boolean
C0348374 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C0348374 (UMLS CUI [2,1])
C1522484 (UMLS CUI [2,2])
Sirolimus | temsirolimus | sunitinib
Item
2. prior therapy with sirolimus, temsirolimus or sunitinib.
boolean
C0072980 (UMLS CUI [1])
C1707080 (UMLS CUI [2])
C1176020 (UMLS CUI [3])
CYP3A4 Inhibitor Strong | CYP3A4 Inducer Strong
Item
3. subjects receiving known strong cytochrome p450 (cyp)3a4 isoenzyme inhibitors and/or inducers. subjects receiving other cyp3a4 isoenzyme inhibitors and/or inducers not classified as strong inhibitors or inducers are eligible, provided they have been on a stable regimen for at least 4 weeks before screening.
boolean
C3830624 (UMLS CUI [1,1])
C0442821 (UMLS CUI [1,2])
C3830625 (UMLS CUI [2,1])
C0442821 (UMLS CUI [2,2])
Criteria Additional
Item
more criteria apply
boolean
C0243161 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
Inclusion criteria Cohort Phase Expanded
Item
inclusion criteria for expanded cohort phase
boolean
C1512693 (UMLS CUI [1,1])
C0599755 (UMLS CUI [1,2])
C0205390 (UMLS CUI [1,3])
C0205229 (UMLS CUI [1,4])
Renal Cell Carcinoma Advanced | Independent of Nephrectomy status | Systemic therapy Absent
Item
1. subjects with histologically confirmed advanced rcc regardless of nephrectomy status who have received no prior systemic therapies for their disease.
boolean
C0007134 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0332291 (UMLS CUI [2,1])
C1404808 (UMLS CUI [2,2])
C1515119 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
Renal Cell Carcinoma Advanced | Independent of Nephrectomy status | Palliative Radiation Therapy | Palliative Surgery | Toxic effects Due to Prior Therapy | Resolution CTCAE Grades
Item
2. subjects with histologically confirmed advanced rcc regardless of nephrectomy status who have a least 4 weeks since prior treatment with palliative radiation therapy, and/or surgery and resolution of all toxic effects of prior therapy to nci ctcae (version 3.0) grade £1.
boolean
C0007134 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0332291 (UMLS CUI [2,1])
C1404808 (UMLS CUI [2,2])
C3898008 (UMLS CUI [3])
C0282282 (UMLS CUI [4])
C0600688 (UMLS CUI [5,1])
C0678226 (UMLS CUI [5,2])
C1514463 (UMLS CUI [5,3])
C1514893 (UMLS CUI [6,1])
C1516728 (UMLS CUI [6,2])
Measurable lesion Quantity | Measurable lesion Dimension Quantity | Longest Diameter Spiral CT | Slice Thickness | Longest Diameter CT
Item
3. subjects must have at least 1 measurable lesion that can be accurately measured in at least 1 dimension with the longest diameter ³10 mm when measured by spiral ct (5-mm slice thickness contiguous) or ³20 mm when measured by conventional ct (10-mm slice thickness contiguous) (lesion must be ³2 times the size of the slice thickness per recist).
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2,1])
C0439534 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0552406 (UMLS CUI [3,1])
C0860888 (UMLS CUI [3,2])
C3829566 (UMLS CUI [4])
C0552406 (UMLS CUI [5,1])
C0040405 (UMLS CUI [5,2])
Criteria Additional
Item
more criteria apply
boolean
C0243161 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
Exclusion Criteria Cohort Phase Expanded
Item
exclusion criteria for the expanded cohort phase
boolean
C0680251 (UMLS CUI [1,1])
C0599755 (UMLS CUI [1,2])
C0205390 (UMLS CUI [1,3])
C0205229 (UMLS CUI [1,4])
Medical History Malignant Central Nervous System Neoplasm | Medical History Neoplasm Metastasis Central Nervous System | Malignant Central Nervous System Neoplasm Primary | Malignant Central Nervous System Neoplasm metastatic
Item
1. subjects with a history of a cns malignancy or metastatic disease to the cns and subjects with a known, active cns malignancy (primary or metastatic).
boolean
C0262926 (UMLS CUI [1,1])
C0348374 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0027627 (UMLS CUI [2,2])
C3714787 (UMLS CUI [2,3])
C0348374 (UMLS CUI [3,1])
C0205225 (UMLS CUI [3,2])
C0348374 (UMLS CUI [4,1])
C1522484 (UMLS CUI [4,2])
Vascular Endothelial Growth Factor Inhibitor | Monoclonal Antibodies | Tyrosine kinase inhibitor | mTOR Inhibitor
Item
2. prior anti-vascular endothelial growth factor (anti-vegf) therapies (with either monoclonal antibodies and/or tyrosine kinase inhibitors [tkis]) and/or mtor inhibitors.
boolean
C4521299 (UMLS CUI [1])
C0003250 (UMLS CUI [2])
C1268567 (UMLS CUI [3])
C2746052 (UMLS CUI [4])
CYP3A4 Inhibitor Strong | CYP3A4 Inducer Strong
Item
3. subjects receiving known strong cyp3a4 isoenzyme inhibitors and/or inducers. subjects taking other cyp3a4 isoenzyme inhibitors and/or inducers not classified as strong inhibitors or inducers are eligible, provided they have been on a stable regimen for at least 4 weeks before screening.
boolean
C3830624 (UMLS CUI [1,1])
C0442821 (UMLS CUI [1,2])
C3830625 (UMLS CUI [2,1])
C0442821 (UMLS CUI [2,2])
Criteria Additional
Item
more criteria apply
boolean
C0243161 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video